Posted by Michael Wonder on 23 Jul 2019
Baxter announces U.S. FDA approval of Myxredlin, the first and only ready-to-use insulin for IV infusion
22 July 2019 - Offers extended shelf life of 30 days at room temperature or 24 months refrigerated.
Baxter International today announced the U.S. FDA approval of Myxredlin (insulin human in 0.9% sodium chloride Injection). Myxredlin is the first and only ready-to-use insulin for IV infusion in the hospital and other acute care settings and features an extended shelf life of 30 days at room temperature (77 degrees F [25 degrees C]) or 24 months if refrigerated (36 degrees F to 46 degrees F [2 degrees C to 8 degrees C]) in the original carton to protect from light. Myxredlin is provided in a standardised concentration of 100 units/100 mL in a flexible plastic container.
This innovative presentation helps ensure Myxredlin delivers a consistent, stable and predictable concentration with every administration, which is a key consideration for patient safety.
